Fig. 1

Consequences of intravitreal administration of AQP4-IgG in rat. a Injection approach. b AQP4 and human IgG immunofluorescence in retinal flat mounts 5 days after intravitreal delivery of 40 μg control human IgG or AQP4-IgG in rat. c Immunofluorescence on transverse retinal sections for experiments as in (b). Representative of 4 eyes per condition. d Relative immunofluorescence of AQP4 (left) and GFAP (right) in indicated retinal layers from sections as in (c) (mean ± S.E.M, 2 rats, 4 eyes per condition, *p < 0.05, **p < 0.01)